Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers

Cancer Biology and Therapy

Volumn 11, Issue 2, 2011, Pages 263-276

  Raja, Srikumar M ^a,b   Clubb, Robert J ^a,b,c   Ortega Cava, Cesar ^a,b   Williams, Stetson H ^a   Bailey, Tameka A ^a   Duan, Lei ^a,b,d   Zhao, Xiangshan ^a,b   Reddi, Alagarasamy L ^b,e   Nyong, Abijah M ^a   Natarajan, Amarnath ^a   Band, Vimla ^a,b   Band, Hamid ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Genzyme Genetics   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

17 AAG; Celastrol; Drug interaction; ErbB2; Her2 Neu; HSP90; Proteasome; ROS; Targeted therapy; Trastuzumab; Ubiquitin

Indexed keywords

CELASTROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; LAPATINIB; REACTIVE OXYGEN METABOLITE; TANESPIMYCIN; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE; PROTEIN DEGRADATION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; UBIQUITINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, SCID; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751506175     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.2.13959     Document Type: Article

References (57)

1. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 2009; 9:419-38.
2. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 2008; 44:2806-12.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-23.
5. Murphy CG, Modi S. HER2 breast cancer therapies: A review. Biologics 2009; 3:289-301.
6. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353:1734-6.
7. Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215.
8. Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann NY Acad Sci 2005; 1059:70-5.
9. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:485-98.
10. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008; 28:5605-20.
11. Neckers L. Heat shock protein 90 is a rational molecular target in breast cancer. Breast Dis 2002; 15:53-60.
12. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3:213-7.
13. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, et al. A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 2008; 7:1630-40.
14. Modi S, Stopeck A, Gordon MS, Solit D, Bagatell R, Flores S, et al. Trastuzumab and KOS-953 (17-AAG) is feasible and active in patients with metastatic breast cancer: Preliminary results of a phase 1/2 study. Presented at the 28th Annual San Antonio Breast Cancer Symposium December 8-11 2005, San Antonio TX.
15. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol 2007; 25:5410-7.
16. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13:1775-82.
17. Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, et al. Inhibition of Hsp90 activates osteoclast c-src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA 2008; 105:15541-6.
18. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10:321-30.
19. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the chinese "thunder of god vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66:4758-65.
20. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NFkappaB-regulated gene products and TAK1-mediated NFkappaB activation. Blood 2007; 109:2727-35.
21. Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res 2007; 13:6769-78.
22. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7:162-70.
23. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008; 111:5654-62.
24. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009; 8:2339-47.
25. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, et al. Inhibition of NFkappaB activation through targeting IkappaB kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006; 72:1311-21.
26. Trott A, West JD, Klaic L, Westerheide SD, Silverman RB, Morimoto RI, et al. Activation of heat shock and antioxidant responses by the natural product celastrol: Transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell 2008; 19:1104-12.
27. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 2009; 8:579-91.
28. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: A vicious cycle or a doubleedged sword? Antioxid Redox Signal 2007; 9:2277-93.
29. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585-92.
30. Roy V, Perez EA. Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 2009; 14:1061-9.
31. Yang H, Shi G, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from "indian winter cherry". Mol Pharmacol 2007; 71:426-37.
32. Sreeramulu S, Gande SL, Gobel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperonecochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 2009; 48:5853-5.
33. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/ Neu. Proc Natl Acad Sci USA 2002; 99:12847-52.
34. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003; 278:13829-37.
35. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, et al. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 2003; 63:7777-84.
36. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000; 60:3940-6.
37. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization and enhances antitumor activity. Mol Cancer Ther 2004; 3:551-66.
38. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: A breath of life or death? Clin Cancer Res 2007; 13:789-94.
39. Cheng G, Diebold BA, Hughes Y, Lambeth JD. Nox1-dependent reactive oxygen generation is regulated by Rac1. J Biol Chem 2006; 281:17718-26.
40. Zhang Q, Chatterjee S, Wei Z, Liu WD, Fisher AB. Rac and PI3 kinase mediate endothelial cell-reactive oxygen species generation during normoxic lung ischemia. Antioxid Redox Signal 2008; 10:679-89.
41. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 2004; 279:56053-60.
42. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42:260-6.
43. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10:241-52.
44. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436:123-7.
45. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008; 14:458-70.
46. Wang K, Fang H, Xiao D, Zhu X, He M, Pan X, et al. Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells. PLoS One 2009; 4:7538.
47. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009; 136:823-37.
48. Adams J. The proteasome as a novel target for the treatment of breast cancer. Breast Dis 2009; 15:61-70.
49. Tsukamoto S, Yokosawa H. Targeting the proteasome pathway. Expert Opin Ther Targets 2009; 13:605-21.
50. Neckers L. Heat shock protein 90 is a rational molecular target in breast cancer. Breast Dis 2009; 15:53-60.
51. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007; 1113:202-16.
52. Hwang M, Moretti L, Lu B. HSP90 inhibitors: Multitargeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem 2009; 16:3081-92.
53. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, et al. Nuclear factorkappaB activation: A molecular therapeutic target for estrogen receptornegative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007; 6:1973-82.
54. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 2010; 9:292-9.
55. Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, et al. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res 1990; 50:7351-7.
56. Bonita DP, Miyake SLLM Jr, Langdon WY, Band H. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of cbl: Implications for cbl's function and oncogenicity. Mol Cell Biol 1997; 17:4597-610.
57. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, et al. 17-allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8:986-93.